Based on promising Phase II data showing a 42% reduction in cognitive decline markers, Zenth-492 advances toward Phase III global trials.
The lipid-nanoparticle cardiovascular vaccine demonstrates exceptional tolerability across diverse demographic groups in multi-center studies.
Joint venture will accelerate precision medicine applications in hemoglobinopathies and rare genetic disorders using next-gen delivery vectors.
Proprietary deep-learning platform successfully predicts binding affinities for resistant bacterial strains, bypassing traditional 24-month screening.
Multi-omic tumor profiling test receives CE-IVD mark, enabling rapid patient stratification for checkpoint inhibitor therapies across Europe.
Double-blind, placebo-controlled study targets treatment-resistant focal epilepsy with transdermal neuro-regenerative compound.